Associated Papers
Impacts of gene variants on drug effects-the foundation of genotype-guided pharmacologic therapy for long QT syndrome and short QT syndrome.
Zhao Z et al.
Ebiomedicine, 2024
hERG stereoselective modulation by mexiletine-derived ureas: Molecular docking study, synthesis, and biological evaluation.
Milani G et al.
Archiv Der Pharmazie, 2023
Investigating the state dependence of drug binding in hERG channels using a trapped-open channel phenotype.
Thouta S et al.
Scientific Reports, 2018
Discovery of a new mexiletine-derived agonist of the hERG K+ channel.
Gualdani R et al.
Biophysical Chemistry, 2017
Molecular Basis of Altered hERG1 Channel Gating Induced by Ginsenoside Rg3.
Gardner A et al.
Molecular Pharmacology, 2017
Molecular Basis of Cardiac Delayed Rectifier Potassium Channel Function and Pharmacology.
Wu W et al.
Cardiac Electrophysiology Clinics, 2016
Getting to the heart of hERG K(+) channel gating.
Perry MD et al.
The Journal of Physiology, 2015
The Link between Inactivation and High-Affinity Block of hERG1 Channels.
Wu W et al.
Molecular Pharmacology, 2015
Cooperative subunit interactions mediate fast C-type inactivation of hERG1 K+ channels.
Wu W et al.
The Journal of Physiology, 2014
Stoichiometry of altered hERG1 channel gating by small molecule activators.
Wu W et al.
The Journal of General Physiology, 2014
Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine.
Thurner P et al.
The Journal of Pharmacology and Experimental Therapeutics, 2014
Current pharmacogenomic studies on hERG potassium channels.
He FZ et al.
Trends in Molecular Medicine, 2013
Structure-guided topographic mapping and mutagenesis to elucidate binding sites for the human ether-a-go-go-related gene 1 potassium channel (KCNH2) activator NS1643.
Durdagi S et al.
The Journal of Pharmacology and Experimental Therapeutics, 2012
hERG K(+) channels: structure, function, and clinical significance.
Vandenberg JI et al.
Physiological Reviews, 2012
A molecular switch driving inactivation in the cardiac K+ channel HERG.
Köpfer DA et al.
Plos One, 2012
Molecular determinants for activation of human ether-à-go-go-related gene 1 potassium channels by 3-nitro-n-(4-phenoxyphenyl) benzamide.
Garg V et al.
Molecular Pharmacology, 2011
Blockade of permeation by potassium but normal gating of the G628S nonconducting hERG channel mutant.
Es-Salah-Lamoureux Z et al.
Biophysical Journal, 2011
Ginsenoside Rg(3) decelerates hERG K(+) channel deactivation through Ser631 residue interaction.
Choi SH et al.
European Journal of Pharmacology, 2011
Mapping the sequence of conformational changes underlying selectivity filter gating in the K(v)11.1 potassium channel.
Wang DT et al.
Nature Structural & Molecular Biology, 2011
PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K+ conductance.
Perry M et al.
Proceedings of the National Academy of Sciences of the United States of America, 2009
Electrophysiologic characterization of a novel hERG channel activator.
Su Z et al.
Biochemical Pharmacology, 2009
Intracellular potassium stabilizes human ether-à-go-go-related gene channels for export from endoplasmic reticulum.
Wang L et al.
Molecular Pharmacology, 2009
Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.
McPate MJ et al.
British Journal of Pharmacology, 2008
Insight into the mechanism of inactivation and pH sensitivity in potassium channels from molecular dynamics simulations.
Stansfeld PJ et al.
Biochemistry, 2008
Probing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243).
Xu X et al.
Molecular Pharmacology, 2008
Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling.
Tseng GN et al.
Biophysical Journal, 2007
Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
Schwoerer AP et al.
Anesthesiology, 2007
Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine.
Siebrands CC et al.
Anesthesiology, 2007
Na+ permeation and block of hERG potassium channels.
Gang H et al.
The Journal of General Physiology, 2006
Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
Guo J et al.
The Journal of Pharmacology and Experimental Therapeutics, 2006
Mechanism of action of a novel human ether-a-go-go-related gene channel activator.
Casis O et al.
Molecular Pharmacology, 2006
Block of HERG channels by berberine: mechanisms of voltage- and state-dependence probed with site-directed mutant channels.
Rodriguez-Menchaca A et al.
Journal of Cardiovascular Pharmacology, 2006
Structural determinants of potassium channel blockade and drug-induced arrhythmias.
Wehrens XH
Handbook of Experimental Pharmacology, 2006
Dynamic conformational changes of extracellular S5-P linkers in the hERG channel.
Jiang M et al.
The Journal of Physiology, 2005
Molecular mapping of a site for Cd2+-induced modification of human ether-à-go-go-related gene (hERG) channel activation.
Fernandez D et al.
The Journal of Physiology, 2005
Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channels: role of aromatic amino acids Y652 and F656.
Siebrands CC et al.
Anesthesiology, 2005
Gating charges in the activation and inactivation processes of the HERG channel.
Zhang M et al.
The Journal of General Physiology, 2004
Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
Sánchez-Chapula JA et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2004
The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ et al.
Molecular Pharmacology, 2004
BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1.
Zhang M et al.
Biophysical Journal, 2003
Structural and functional role of the extracellular s5-p linker in the HERG potassium channel.
Liu J et al.
The Journal of General Physiology, 2002
Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.
Sánchez-Chapula JA et al.
The Journal of Biological Chemistry, 2002
Characterization of a novel missense mutation E637K in the pore-S6 loop of HERG in a patient with long QT syndrome.
Hayashi K et al.
Cardiovascular Research, 2002
Dofetilide block involves interactions with open and inactivated states of HERG channels.
Weerapura M et al.
Pflugers Archiv : European Journal of Physiology, 2002
Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
Ficker E et al.
Molecular Pharmacology, 2001
Probing the interaction between inactivation gating and Dd-sotalol block of HERG.
Numaguchi H et al.
Circulation Research, 2000
Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel.
Walker BD et al.
Cardiovascular Research, 2000
Altered gating of HERG potassium channels by cobalt and lanthanum.
Sanchez-Chapula JA et al.
Pflugers Archiv : European Journal of Physiology, 2000
Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation.
Ulens C et al.
Febs Letters, 2000
Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.
Mitcheson JS et al.
The Journal of General Physiology, 2000